Show simple item record

Paclitaxel, Not Bevacizumab, Was Primarily Responsible for the Favorable Effects Seen in the RIBBON-2 Trial

dc.contributor.authorKesikli, Altug
dc.contributor.authorKilickap, Saadettin
dc.date.accessioned2019-07-27T12:10:23Z
dc.date.accessioned2019-07-28T10:04:06Z
dc.date.available2019-07-27T12:10:23Z
dc.date.available2019-07-28T10:04:06Z
dc.date.issued2012
dc.identifier.issn0732-183X
dc.identifier.urihttps://dx.doi.org/10.1200/JCO.2011.40.2305
dc.identifier.urihttps://hdl.handle.net/20.500.12418/9237
dc.descriptionWOS: 000302620900029en_US
dc.descriptionPubMed ID: 22203773en_US
dc.description.abstract…en_US
dc.language.isoengen_US
dc.publisherAMER SOC CLINICAL ONCOLOGYen_US
dc.relation.isversionof10.1200/JCO.2011.40.2305en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titlePaclitaxel, Not Bevacizumab, Was Primarily Responsible for the Favorable Effects Seen in the RIBBON-2 Trialen_US
dc.typeletteren_US
dc.relation.journalJOURNAL OF CLINICAL ONCOLOGYen_US
dc.contributor.department[Kesikli, Altug] Hacettepe Univ, Inst Oncol, Ankara, Turkey -- [Kilickap, Saadettin] Cumhuriyet Univ, Sivas, Turkeyen_US
dc.identifier.volume30en_US
dc.identifier.issue4en_US
dc.identifier.endpage461en_US
dc.identifier.startpage461en_US
dc.relation.publicationcategoryDiğeren_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record